Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals

Sci Rep. 2018 Apr 16;8(1):6030. doi: 10.1038/s41598-018-24463-3.

Abstract

Aggregation of TAR DNA-binding protein of 43 kDa (TDP-43) is implicated in the pathogenesis of sporadic and certain familial forms of amyotrophic lateral sclerosis (ALS), suggesting elimination of TDP-43 aggregates as a possible therapeutic strategy. Here we generated and investigated a single-chain variable fragment (scFv) derived from the 3B12A monoclonal antibody (MAb) that recognises D247 of the TDP-43 nuclear export signal, an epitope masked in the physiological state. In transfected HEK293A cells, 3B12A scFv recapitulated the affinity of the full-length MAb to mislocalised TDP-43 with a defective nuclear localising signal and to a TDP-43 inclusion mimic with cysteine-to-serine substitution at RRM1. Moreover, 3B12A scFv accelerated proteasome-mediated degradation of aggregated TDP-43, likely due to an endogenous PEST-like proteolytic signal sequence in the VH domain CDR2 region. Addition of the chaperone-mediated autophagy (CMA)-related signal to 3B12A scFv induced HSP70 transcription, further enhancing TDP-43 aggregate clearance and cell viability. The 3B12A scFv also reduced TDP-43 aggregates in embryonic mouse brain following in utero electroporation while causing no overt postnatal brain pathology or developmental anomalies. These results suggest that a misfolding-specific intrabody prone to synergistic proteolysis by proteasomal and autophagic pathways is a promising strategy for mitigation of TDP-43 proteinopathy in ALS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Amyotrophic Lateral Sclerosis / drug therapy*
  • Amyotrophic Lateral Sclerosis / metabolism
  • Amyotrophic Lateral Sclerosis / pathology
  • Animals
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal / therapeutic use
  • Autophagy / drug effects
  • DNA-Binding Proteins / analysis
  • DNA-Binding Proteins / metabolism*
  • HEK293 Cells
  • HSP70 Heat-Shock Proteins / metabolism
  • Humans
  • Inclusion Bodies / drug effects
  • Inclusion Bodies / metabolism
  • Inclusion Bodies / pathology
  • Mice, Inbred ICR
  • Protein Aggregation, Pathological / drug therapy*
  • Protein Aggregation, Pathological / metabolism
  • Protein Aggregation, Pathological / pathology
  • Protein Folding / drug effects*
  • Proteolysis
  • Proteostasis Deficiencies / drug therapy
  • Proteostasis Deficiencies / metabolism
  • Proteostasis Deficiencies / pathology
  • Single-Chain Antibodies / pharmacology*
  • Single-Chain Antibodies / therapeutic use

Substances

  • Antibodies, Monoclonal
  • DNA-Binding Proteins
  • HSP70 Heat-Shock Proteins
  • Single-Chain Antibodies
  • TARDBP protein, human